These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24712857)

  • 41. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
    Scott LJ; Lyseng-Williamson KA
    BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses.
    Kontaki E; Boumpas DT; Tzardi M; Mouzas IA; Papadakis KA; Verginis P
    Autoimmunity; 2017 May; 50(3):170-181. PubMed ID: 28276713
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lenalidomide in multiple myeloma.
    Kim Y; Schmidt-Wolf IG
    Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
    Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
    Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
    Raja KR; Plasil M; Rihova L; Pelcova J; Adam Z; Hajek R
    Cytometry B Clin Cytom; 2014 Jul; 86(4):220-8. PubMed ID: 23922218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
    Madan S; Lacy MQ; Dispenzieri A; Gertz MA; Buadi F; Hayman SR; Detweiler-Short K; Dingli D; Zeldenrust S; Lust J; Greipp PR; Rajkumar SV; Kumar S
    Blood; 2011 Aug; 118(7):1763-5. PubMed ID: 21673347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
    Kneppers E; van der Holt B; Kersten MJ; Zweegman S; Meijer E; Huls G; Cornelissen JJ; Janssen JJ; Huisman C; Cornelisse PB; Bruijnen CP; Emmelot M; Sonneveld P; Lokhorst HM; Mutis T; Minnema MC
    Blood; 2011 Sep; 118(9):2413-9. PubMed ID: 21690556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lenalidomide and T-cell homeostasis: tolerating immune reconstitution after autologous stem cell transplant.
    Perry C; Polliack A
    Leuk Lymphoma; 2014 Aug; 55(8):1699-700. PubMed ID: 24410588
    [No Abstract]   [Full Text] [Related]  

  • 53. [Development of thalidomide analogs for the treatment of multiple myeloma (MM)].
    Chou T
    Nihon Rinsho; 2007 Dec; 65(12):2302-8. PubMed ID: 18069277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The use of lenalidomide in the treatment of multiple myeloma].
    Holánek M; Hájek R
    Klin Onkol; 2010; 23(2):67-72. PubMed ID: 20465083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
    Syed YY
    Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Immunomodulator drugs for the treatment of multiple myeloma].
    Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
    Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
    Xu G; Wang B; Yang M; Qian W
    Int J Clin Exp Pathol; 2015; 8(11):15025-9. PubMed ID: 26823839
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
    Vallet S; Palumbo A; Raje N; Boccadoro M; Anderson KC
    Leuk Lymphoma; 2008 Jul; 49(7):1238-45. PubMed ID: 18452080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
    Scott LJ; Lyseng-Williamson KA
    Drugs; 2011 Mar; 71(5):625-49. PubMed ID: 21443285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.